David Sinclair· PhD
"The treatment, called ER-100, has received FDA clearance and is entering Phase 1 human trials."
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
"The treatment, called ER-100, has received FDA clearance and is entering Phase 1 human trials."
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
"In animal studies, the same approach restored vision by rejuvenating damaged nerve cells."
"The first targets are age-related eye diseases like glaucoma and optic nerve damage."
On track to test ER-100 epigenetic age reversal in glaucoma & NAION patients early 2026.